ZANTAC

This brand name is authorized in Australia, Canada, Cyprus, Estonia, Hong Kong SAR China, Lithuania, New Zealand, Poland, Singapore, South Africa, Turkey, United States.

Active ingredients

The drug ZANTAC contains one active pharmaceutical ingredient (API):

1	Ranitidine UNII BK76465IHM - RANITIDINE HYDROCHLORIDE
	Ranitidine is a specific rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion. Ranitidine has a relatively long duration of action and so a single 150 mg dose effectively suppresses gastric acid secretion for twelve hours.
	Read more about Ranitidine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZANTAC Injection (Aqueous solution)	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
ZANTAC Tablets	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A02BA02	Ranitidine	A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BA H2-receptor antagonists
Discover more medicines within A02BA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1977C, 1978D, 8162N
CA	Health Products and Food Branch	02230287, 02277301
EE	Ravimiamet	1005444, 1005477, 1061525, 1061930, 1061941
HK	Department of Health Drug Office	30459, 42045, 42792, 42793
LT	Valstybinė vaistų kontrolės tarnyba	1062787
NZ	Medicines and Medical Devices Safety Authority	10203, 12270, 13591, 3009
PL	Rejestru Produktów Leczniczych	100072404, 100072410
SG	Health Sciences Authority	02428P, 02543P, 12111P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699522022359
US	FDA, National Drug Code	52565-096, 52565-101, 52565-102
ZA	Health Products Regulatory Authority	28/11.4.3/0437, 28/11.4.3/0438, 28/11.4.3/0439, 30/11.4.3/0040, 35/11.4.3/0341, P/11.4.3/218, S/11.4.3/102, S/11.4.3/378, W/11.4.3/277, Z/11.4.3/303, Z/11.4.3/304